International Journal of Cancer Management

Published by: Kowsar

The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer

Haniyeh Bashizadeh-Fakhar 1 , Mostafa Rezaie-Tavirani 1 , * , Hakimeh Zali 2 , Roya Faraji 3 , Ehsan Kazem Nejad 4 and Mohamadhossein Aghazadeh 5
Authors Information
1 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Proteomics Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Reproductive Health Research Center, Department of Obstetrics and Gynecology, Guilan University of Medical Sciences, Rasht, IR Iran
4 Departments of Biostatistics, Guilan Road Truma Research Center, Guilan University of Medical Sciences, Rasht, IR Iran
5 Azad Medical University, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: May 2018, 11 (5); e63397
  • Published Online: May 12, 2018
  • Article Type: Research Article
  • Received: November 11, 2017
  • Revised: December 17, 2017
  • Accepted: December 23, 2017
  • DOI: 10.5812/ijcm.63397

To Cite: Bashizadeh-Fakhar H, Rezaie-Tavirani M, Zali H, Faraji R, Kazem Nejad E, et al. The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer, Int J Cancer Manag. 2018 ;11(5):e63397. doi: 10.5812/ijcm.63397.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Smith LH, Oi RH. Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv. 1984;39(6):313-28. [PubMed: 6374536].
  • 2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3-10. [PubMed: 10883018].
  • 3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi: 10.3322/caac.21166. [PubMed: 23335087].
  • 4. Zhang Z, Bast RJ, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64(16):5882-90. doi: 10.1158/0008-5472.CAN-04-0746. [PubMed: 15313933].
  • 5. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S145-60. doi: 10.1016/S0020-7292(06)60032-5. [PubMed: 17161156].
  • 6. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. [PubMed: 22835718].
  • 7. Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol. 1995;57(2):178-82. doi: 10.1006/gyno.1995.1121. [PubMed: 7729730].
  • 8. Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012;67(5):437-41. [PubMed: 22666786]. [PubMed Central: PMC3351260].
  • 9. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RJ, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117(3):440-5. doi: 10.1016/j.ygyno.2010.02.005. [PubMed: 20334903]. [PubMed Central: PMC2873171].
  • 10. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30(3):121-9. doi: 10.1159/000224628. [PubMed: 19506400].
  • 11. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. [PubMed: 18851871]. [PubMed Central: PMC3594094].
  • 12. Li F, Tie R, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012;12:258. doi: 10.1186/1471-2407-12-258. [PubMed: 22712526]. [PubMed Central: PMC3443004].
  • 13. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(3):228 e1-6. doi: 10.1016/j.ajog.2010.03.043. [PubMed: 20471625]. [PubMed Central: PMC3594101].
  • 14. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100(2):195-9. doi: 10.1111/j.1349-7006.2008.01022.x. [PubMed: 19200256].
  • 15. Kim DY, Kim HR, Shim JH, Park CS, Kim SK, Kim YJ. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000;74(3):185-92. [PubMed: 10951413].
  • 16. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study. Pathology. 2008;40(5):487-92. doi: 10.1080/00313020802197889. [PubMed: 18604735].
  • 17. Hori SS, Gambhir SS. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med. 2011;3(109):109ra116. doi: 10.1126/scitranslmed.3003110. [PubMed: 22089452]. [PubMed Central: PMC3423335].
  • 18. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11-7. doi: 10.1111/j.1525-1438.2006.00319.x. [PubMed: 16515561].
  • 19. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589-98. doi: 10.1002/cncr.21616. [PubMed: 16369985].
  • 20. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. [PubMed: 23200911].
  • 21. Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, et al. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. Oncol Res Treat. 2015;38(6):276-81. doi: 10.1159/000430858. [PubMed: 26045023].
  • 22. Kaijser J, Van Gorp T, Smet ME, Van Holsbeke C, Sayasneh A, Epstein E, et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography? Ultrasound Obstet Gynecol. 2014;43(1):89-97. doi: 10.1002/uog.12551. [PubMed: 23828371].
  • 23. Pitynski K, Sporek A, Lipinska I, Banas T, Ludwin A, Balajewicz-Nowak M. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study. Taiwan J Obstet Gynecol. 2015;54(6):766-72. doi: 10.1016/j.tjog.2015.10.006. [PubMed: 26701000].
  • 24. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. [PubMed: 19282241].
  • 25. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775-82. doi: 10.1097/AOG.0b013e31819cda77. [PubMed: 19305319]. [PubMed Central: PMC2728067].
  • 26. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. [PubMed: 18584856].
  • 27. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. [PubMed: 19337252]. [PubMed Central: PMC2676558].
  • 28. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol. 1990;39(1):26-33. [PubMed: 2227570].
  • 29. Sorensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull. 2011;58(11). A4331. [PubMed: 22047929].
  • 30. Mediu R, Marku E, Mediu N. Simultaneous measurements of different tumor markers for early detection of ovarian cancer. Interdisplinar J Res Dev. 2017;2(4):55-62.
  • 31. Guo J, Yu J, Song X, Mi H. Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis. Open Med (Wars). 2017;12:131-7. doi: 10.1515/med-2017-0020. [PubMed: 28730172]. [PubMed Central: PMC5471922].
  • 32. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. [PubMed: 20368574]. [PubMed Central: PMC2860434].
  • 33. Jafari-Shobeiri M, Parizad M, Nazari F, Ouladsahebmadarek E, Sayyah-Melli M, Mostafa-Gharabaghi P, et al. Diagnostic Value of HE4, CA125 and Risk of Ovarian Malignancy Algorithm in Detecting Ovarian Cancer. International Journal of Women's Health and Reproduction Sciences. 2015;3(4):208-11. doi: 10.15296/ijwhr.2015.43.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments